Lexaria’s after-hours surge came after the company filed with the Securities and Exchange Commission on Thursday, revealing that it had ended its “Capital on Demand” Sales Agreement with JonesTrading ...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F ...
Lexaria Bioscience Corp (NASDAQ:LEXX) shares are trading lower by 6.5% to $2.43 Thursday morning after the company finalized agreements for a registered direct offering of 1,558,443 shares of common ...
LEXARIA BIOSCIENCE ($LEXX) is expected to release its quarterly earnings data on Thursday, July 10th before market open, per Finnhub. Analysts are expecting revenue ...
TipRanks on MSN
Lexaria’s phase 1b GLP-1 study shows comparable metabolic outcomes and encouraging blood pressure data for DehydraTECH platform
Lexaria Bioscience ( ($LEXX) ) has issued an update. Lexaria released additional secondary and exploratory results from its 12‑week Phase 1b ...
Lexaria Bioscience Corp. Annual cash flow by MarketWatch. View LEXX net cash flow, operating cash flow, operating expenses and cash dividends.
Lexaria Bioscience (NASDAQ:LEXX) was trading lower after the drug delivery platform announced a sale of 2,666,667 shares, par value $0.001 per share, at $1.50 per share in a registered direct offering ...
TipRanks on MSN
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026
Lexaria Bioscience ( ($LEXX) ) just unveiled an update. Lexaria reported that its Phase 1b, 12‑week chronic study GLP-1-H24-4 in Australia met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback